Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines

Table 1 Primer sequences used in RT-PCR analysis.

Gene	Size of PCR (bp)	Forward primer	Reverse primer
DPD	514	TCCTCCAGGTATGCAGTGCCA	GTTATGGTGGGCAGGTGGGTT
GAPDH	328	CAACAGCCTCAAGATCATCAGC	TTCTAGACGGCAGGTCAGGTC
GSTP1	199	TACGGGCAGCTCCCCAAGTT	TGCCCGCCTCATAGTTGGTG
MDR1	206	GTCTTTGGTGCCATGGCCGT	ATGTCCGGTCGGGTGGGATA
MRP1	262	CTGACAAGCTAGACCATGAATGT	CCTTTGTCCAAGACGATCACCC
MRP2	202	GCCAGATTGGCCCAGCAAA	AATCTGACCACCGGCAGCCT
MRP3	452	GGGACCCTGCGCATGAACCTG	TAGGCAAGTCCAGCATCTCTGG
TS	579	GAATCACATCGAGCCACTGAAA	GTGTTACTCAGCTCCCTCAGA

Table 2 IC₅₀ values of chemotherapeutic agents on CCA cell lines.

Drug	IC50 (mmol/L)
	Poorly differentiated		Moderately differentiated		Well differentiated
	KKU-100	KKU-M055	KKU-M156	KKU-M214	KKU-OCA17
Anthracyclins
Doxorubicin	2.3±0.8b	0.04±0.02	1.8±1.0b	0.25±0.05	0.84±0.83
Pirarubicin	0.27±0.22a	0.01±0.01	0.35±0.06b	0.17±0.03b	0.13±0.05b
Platinum derivatives
Cisplatin	37±3b	0.05±0.01	222±38b	130±12b	6.22±0.19b
Carboplatin	13±3b	0.26±0.01	229±36b	107±4b	10.4±2.7a
Oxaliplatin	71.7±38.7a	0.11±0.00	7.0±4.7	38.0±6.7b	6.8±1.3b
Pyrimidine analog
5-Fluorouracil	1 018±326d	46±42c	144±55d	29.1±17.6b	3.46±0.91
Taxanes
Paclitaxel	39.0±6.8b	0.0030±0.0001	10.9±5.8a	2.62±0.75a	12.5±1.9b
Docetaxel	41.2±7.2b	0.00002±0.00002	0.80±0.36a	12.4±3.7a	1.3±0.3b
Vinca-alkaloids
Vincristine	216.2±52.1d	2.05±0.68c	0.97±0.64	85±19d	0.82±0.17
Vinorabine	2.1±0.2b	0.13±0.01	0.23±0.01a	164±120	0.64±0.17a
Others
Etoposide	416±131b	0.04±0.01	274±217b	54±26a	126±88a
Irinotecan	23±6a	3.41±0.51	13.1±2.1b	43±9b	3.60±1.16
Mitomycin C	45±2b	0.01±0.00	187±0b	78±32a	5.07±0.17b

Data represents mean±SD of at least three experiments.

^aP<0.05,

^bP<0.01 vs KKU-M055;

^cP<0.05,

^dP<0.01 vs KKU-OCA17.